

Reference:	FOI.12850.23
Subject:	New biologic medications within dermatology and respiratory medicine
Date of Request:	11 October 2023

Requested:

Q1. How many patients were treated in September 2023 (or latest available month) by the Dermatology department with the following drugs:

- Abrocitinib (Cibinqo)
- Baricitinib (Olumiant)
- Dupilumab (Dupixent)
- Omalizumab (Xolair)
- Tralokinumab (Adtralza)
- Upadacitinib (Rinvoq)

Q2. How many patients were treated in September 2023 (or latest available month) by the Respiratory Medicine department with the following drugs:

- Benralizumab (Fasenra)
- Dupilumab (Dupixent)
- Mepolizumab (Nucala)
- Omalizumab (Xolair)
- Reslizumab (Cinqaero)
- Tezepelumab (Tezspire)

Response:

1. Hywel Dda University Health Board (UHB) provides, within the table below, the number of patients treated by the Dermatology Department, with the listed biologic medicines, during September 2023.

Medicine	Number
Abrocitinib	0
Baricitinib	0
Dupilumab	27
Omalizumab	9
Tralokinumab	*
Upadacitinib	*

2. The UHB provides, within the table below, the number of patients treated by the Respiratory Department, with the listed biologic medicines, during September 2023.

Medicine	Number
Benralizumab	27
Dupilumab	8
Mepolizumab	10
Omalizumab	0
Reslizumab	0
Tezepelumab	*

Where the figures in the tables provided have been replaced with an asterisk (*), the UHB is unable to provide you with the exact number of patients due to the low numbers of cases (less than 5), as there is a potential risk of identifying individuals if this was disclosed. The UHB is therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This information is protected by the Data Protection Act 2018 (DPA)/ UK General Data Protection Regulations (GDPR), as its disclosure would constitute unfair and unlawful processing and would be contrary to the principles and articles of the UK GDPR. This exemption is absolute and therefore there is no requirement to apply the public interest test.

In reaching this decision, the DPA and UK GDPR define personal data as data that relates to a living individual who can be identified solely from that data or from that data and other information, which is in the possession of the data controller.